Key result
TNF-alpha decreased SERCA2a expression by increasing DNA methyltransferase levels and enhancing methylation in the SERCA2a promoter region in HL-1 cardiomyocytes.
Why the study?
Does TNF-alpha decrease SERCA2a expression via promoter methylation in HL-1 cardiomyocytes?
Does TNF-alpha decrease SERCA2a expression via promoter methylation in HL-1 cardiomyocytes?
TNF-alpha decreases SERCA2a expression in cardiomyocytes by increasing DNA methyltransferase levels and enhancing promoter methylation, suggesting hypermethylation inhibition as a potential therapeutic target for cardiac dysfunction.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; leaves open whether methylation inhibition improves cardiac function in vivo.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kao et al. (2009) studied Cardiac dysfunction. TNF-alpha vs. Without TNF-alpha or with co-administration of inhibitors was evaluated on SERCA2a RNA and protein expression, and methylation in the SERCA2a promoter region. TNF-alpha decreased SERCA2a expression by increasing DNA methyltransferase levels and enhancing methylation in the SERCA2a promoter region in HL-1 cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: